Learn More
TCR V beta 8.1/8.2 Monoclonal Antibody (KJ16-133 (KJ-16, KJI6, KJ-I6)), FITC, eBioscience™, Invitrogen™
Rat Monoclonal Antibody
£79.00 - £96.75
Specifications
Antigen | TCR V beta 8.1/8.2 |
---|---|
Concentration | 0.5 mg/mL |
Applications | Flow Cytometry |
Classification | Monoclonal |
Conjugate | FITC |
Code produit | Marque | Quantity | Prix | Quantité et disponibilité | |||||
---|---|---|---|---|---|---|---|---|---|
Code produit | Marque | Quantity | Prix | Quantité et disponibilité | |||||
15268269
|
Affymetrix eBioscience
11-5813-82 |
100 μg |
£96.75
100µg |
Estimated Shipment: 26-04-2024 Log in to see stock. |
Please sign in to purchase this item. Need a web account? Register with us today! | ||||
15258269
|
Affymetrix eBioscience
11-5813-81 |
50 μg |
This item is currently unavailable or has been discontinued. View the product page for possible alternatives. |
||||||
Description
Description: This KJ16-133 monoclonal antibody recognizes mouse T cell receptors (TCR) containing Vbeta 8.1 or 8.2, which is expressed by 15-20% of peripheral T cells in most strains of mice (ie. Balb/c, AKR, C57BL/6, B10.A) and by a number of T cell hybridomas (ie. DO-11.10, 3DT-52.5, D1G10G11, SKK-9.11, SKK-45.10, MDK16, S18.4). Applications Reported: This KJ16-133 (KJ-16, KJI6, KJ-I6) antibody has been reported for use in flow cytometric analysis. Applications Tested: This KJ16 (KJ-16, KJI6, KJ-I6) antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 μm post-manufacturing filtered.
The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response. TCR recognition of self-peptides has been linked to autoimmune disease. Mutant self-peptides have been associated with tumors. Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome. Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The autoantibodies block TH1-mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for disease. Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP). A small number of T cells lack both CD4 and CD8 (double negative, DN). Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders. Gamma-delta T cells are primarily found within the epithelium. They show less TCR diversity and recognize antigens differently than alpha-beta T cells. Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.Spécification
TCR V beta 8.1/8.2 | |
Flow Cytometry | |
FITC | |
Rat | |
Mouse | |
Primary | |
4° C, store in dark, DO NOT FREEZE! |
0.5 mg/mL | |
Monoclonal | |
Liquid | |
RUO | |
IgG2a κ | |
Affinity chromatography | |
Antibody |
For Research Use Only.